May 4, 2014

Treatment Advice on the Latest Hepatitis C Drugs Sovaldi and Olysio – Released by the VA

Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations

Recommendations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health (March 27, 2014; data last reviewed on March 6, 2014)

The following treatment considerations are based on available medical evidence and represent the opinion of an expert panel of VA HCV clinicians. The purpose of this document is to provide a detailed algorithmic approach to assist in clinical decision-making on HCV treatment considerations based on specific patient characteristics including genotype, treatment history, presence of cirrhosis, and interferon eligibility. The practitioner should interpret these treatment considerations in the clinical context of the individual patient. The content of this document is dynamic and will be revised periodically as new information becomes available.This document is intended to supplement the Veterans Affairs (VA) Pharmacy Benefits Management (PBM) Criteria For Use documents for HCV antivirals. Information in this document may be used to support treatment decisions based on the existing PBM Criteria For Use documents.

Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations (March 27, 2014)


No comments:

Post a Comment